A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas - Bongiovanni, Alberto; Liverani, Chiara; Foca, Flavia; Bergamo, Francesca; Leo, Silvana; Pusceddu, Sara; Gelsomino, Fabio; Brizzi, Maria Pia; Di Meglio, Giovanni; Spada, Francesca; Tamberi, Stefano; Lolli, Ivan; et al. (European journal of cancer (1990), 2024)
Keywords: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Camptothecin - adverse effects; Camptothecin - analogs & derivatives; Camptothecin - therapeutic use; Captem; Carcinoma, Neuroendocrine - blood; Carcinoma, Neuroendocrine - drug therapy; Carcinoma, Neuroendocrine - mortality; Carcinoma, Neuroendocrine - pathology; Circulating miRNA; Etoposide - administration & dosage; Etoposide - adverse effects; Etoposide - therapeutic use; Female; Fluorouracil - adverse effects; Fluorouracil - therapeutic use; Folfiri; Humans; Leucovorin - adverse effects; Leucovorin - therapeutic use; Male; Middle Aged; Neuroendocrine carcinomas (NECs); Phase II trial; Progression-Free Survival; Temozolomide - adverse effects; Temozolomide - therapeutic use; Captem; Circulating miRNA; Neuroendocrine carcinomas (NECs); Folfiri; Phase II trial